

## **Supplemental material**

## List of RAF and RENO-Extend Investigators

Maurizio Paciaroni<sup>1</sup>, MD; Giancarlo Agnelli<sup>1</sup>, MD; Valeria Caso<sup>1</sup>, PhD; Cecilia Becattini<sup>1</sup>, MD; Maria Giulia Mosconi<sup>1</sup> MD, Michela Giustozzi<sup>1</sup>, MD; Georgios Tsivgoulis<sup>2</sup>, MD; David Julian Seiffge<sup>3,4</sup>, MD; Stefan T. Engelter<sup>3</sup>, MD; Philippe Lyrer<sup>3</sup>, MD, Alexandros A. Polymeris<sup>3</sup>, MD; Tolga Dittrich<sup>3</sup>, MD; Annaelle Zietz<sup>3</sup>, MMed; Jukka Putaala<sup>5</sup>, MD; Daniel Strbian<sup>5</sup>, PhD; Liisa Tomppo<sup>5</sup>, MD; Patrik Michel<sup>6</sup>, MD; Davide Strambo<sup>6</sup>, MD; Alexander Salerno<sup>6</sup>, MD; Suzette Remillard<sup>6</sup>, PNC; Manuela Buehrer<sup>6</sup>, PNC; Odessa Bavaud<sup>6</sup>, CORP; Peter Vanacker<sup>7,8,9</sup>, PhD; Susanna M. Zuurbier<sup>7,8</sup>, MD; Laetitia Yperzeele<sup>7,8</sup>, PhD; Caroline M.J. Loos<sup>7,8</sup>, PhD; Manuel Cappellari<sup>10</sup>, MD; Andrea Emiliani<sup>10</sup>, MD; Marialuisa Zedde<sup>11</sup>, MD; Azmil H. Abdul-Rahim<sup>12,13</sup>, MD; Jesse Dawson<sup>13</sup>, MD; Robert Cronshaw<sup>13</sup>, MB BChir; Erika Schirinzi<sup>14</sup>, MD; Massimo Del Sette<sup>14</sup>, MD; Christoph Stretz<sup>15</sup>, MD; Narendra Kala<sup>15</sup>, MD; Michael Reznik<sup>15</sup>, MD; Ashley Schomer<sup>15</sup>, MD; Brian Mac Grory<sup>15,16</sup>, MB, BCh, BAO, MRCP; Mahesh Jayaraman<sup>15</sup>, MD; Shadi Yaghi<sup>15</sup>, MD; Karen L. Furie<sup>15</sup>, MD, MPH; Luca Masotti<sup>17</sup>, MD; Elisa Grifoni<sup>17</sup>, MD; Danilo Toni<sup>18</sup>, MD; Angela Risitano<sup>18</sup>, MD; Anne Falcou<sup>19</sup>, MD; Luca Petraglia<sup>18</sup>, MD; Enrico Maria Lotti<sup>20</sup>, MD; Marina Padroni<sup>21</sup>, MD; Lucia Pavolucci<sup>20</sup>, MD; Piergiorgio Lochner<sup>22</sup>, MD; Giorgio Silvestrelli<sup>23</sup>, PhD; Alfonso Ciccone<sup>23</sup>, MD; Andrea Alberti<sup>1</sup>, MD; Michele Venti<sup>1</sup>, PhD; Ilaria Leone De Magistris<sup>1</sup>, MD; Virginia Cancelloni<sup>1</sup>, MD; Odysseas Kargiotis<sup>24</sup>, MD; Alessandro Rocco<sup>25</sup>, MD; Marina Diomedi<sup>25</sup>, MD; Simona Marcheselli<sup>26</sup>, MD; Pietro Caliandro<sup>27</sup>, MD; Aurelia Zauli<sup>28</sup>, MD; Giuseppe Reale<sup>28</sup>, MD; Marco Moci<sup>28</sup>, MD; Kateryna Antonenko<sup>4,29</sup>, MD; Eugenia Rota<sup>30</sup>, MD; Tiziana Tassinari<sup>31</sup>, MD; Valentina Saia<sup>31</sup>, PhD; Francesco Palmerini<sup>32</sup>, MD; Paolo Aridon<sup>33</sup>, PhD; Valentina Arnao<sup>34</sup>, PhD; Serena Monaco<sup>34</sup>, MD; Salvatore Cottone<sup>34</sup>, MD; Antonio Baldi<sup>35</sup>, MD; Cataldo D'Amore<sup>35</sup>, MD; Walter Ageno<sup>36</sup>, MD; Samuela Pegoraro<sup>36</sup>, MD; George Ntaios<sup>37</sup>, MD; Dimitrios Sagris<sup>37</sup>, MD; Sotirios Giannopoulos<sup>38</sup>, MD; Maria Kosmidou<sup>38</sup>, MD; Evangelos Ntais<sup>38</sup>, MD; Michele Romoli<sup>39</sup>, MD; Leonardo Pantoni<sup>40</sup>, MD, PhD; Silvia Rosa<sup>41</sup>, MD; Pierluigi Bertora<sup>40</sup>, MD; Alberto Chiti<sup>42</sup>, MD; Isabella Canavero<sup>43,44</sup>, MD; Carlo Emanuele Saggese<sup>45</sup>, MD; Maurizio Plocco<sup>45</sup>, MD; Elisa Giorli<sup>46</sup>, MD; Lina Palaiodimou<sup>2</sup>, MD; Eleni

Bakola<sup>2</sup>, MD; Fabio Bandini<sup>47</sup>, MD; Antonio Gasparro<sup>48</sup>, MD; Valeria Terruso<sup>48</sup>, MD; Marina Mannino<sup>48</sup>, MD; Alessandro Pezzini<sup>49</sup>, MD; Andrea Morotti<sup>49</sup>, MD; Mauro Magoni<sup>49</sup>, MD; Raffaele Ornello<sup>50</sup>, MD; Simona Sacco<sup>50</sup>, MD; Nemanja Popovic<sup>51</sup>, MD; Umberto Scoditti<sup>52</sup>, MD; Antonio Genovese<sup>52</sup>, MD; Licia Denti<sup>53</sup>, MD; Yuriy Flomin<sup>54</sup>, MD; Michelangelo Mancuso<sup>55</sup>, MD; Elena Ferrari<sup>55</sup>, MD; Maria Chiara Caselli<sup>55</sup>, MD; Leonardo Ulivi<sup>55</sup>, MD; Nicola Giannini<sup>55</sup>, MD; Kostantinos Vadikolias<sup>56</sup>, MD; Chrysoula Liantinioti<sup>2</sup>, MD; Maria Chondrogianni<sup>2</sup>, MD; Monica Carletti<sup>10</sup>, MD; Efstathia Karagkiozi<sup>37</sup>, MD; George Athanasakis<sup>37</sup>, MD; Kostantinos Makaritsis<sup>37</sup>, MD; Alessia Lanari<sup>57</sup>, MD, PhD; Turgut Tatlisumak<sup>58</sup>, MD; Monica Acciarresi<sup>59</sup>, MD; Vieri Vannucchi<sup>16</sup>, MD; Gianni Lorenzini<sup>60</sup>, MD; Rossana Tassi<sup>61</sup>, MD; Francesca Guideri<sup>61</sup>, MD; Maurizio Acampa<sup>61</sup>, MD; Giuseppe Martini<sup>61</sup>, MD; Sung-Il Sohn<sup>62</sup>, MD, PhD; Nicola Mumoli<sup>63</sup>, MD; Prasanna Tadi<sup>64</sup>, MD; Federica Letteri<sup>18</sup>, MD; Miriam Maccarrone<sup>65</sup>, MD; Franco Galati<sup>66</sup>, MD; Cindy Tiseo<sup>50</sup>, MD; Vanessa Gourbali<sup>67</sup>, MD; Panagiotis Halvatsiotis<sup>68</sup>, MD; Giovanni Orlandi<sup>55</sup>, MD; Martina Giuntini<sup>69</sup>, MD; Francesco Corea<sup>59</sup>, MD, PhD; Marta Bellesini<sup>36</sup>, MD; Mario Maimone Baronello<sup>34</sup>, MD; Theodore Karapanayiotides<sup>70</sup>, MD, PhD; Christina Rueckert<sup>71</sup>, MD; Laszló Csiba<sup>72</sup>, MD; Lilla Szabó<sup>72</sup>, MD; Alberto Rigatelli<sup>10</sup>, MD; Davide Imberti<sup>73</sup>, MD; Dorjan Zabzuni<sup>73</sup>, MD; Alessio Pieroni<sup>74</sup>, MD; Kristian Barlinn MD<sup>75</sup>, Lars-Peder Pallesen MD<sup>75</sup>, Jessica Barlinn MD<sup>75</sup>; Boris Doronin<sup>76</sup>, MD; Vera Volodina<sup>76</sup>, MD; Dirk Deleu<sup>77</sup>, MD, PhD, FRCP; Bruno Bonetti<sup>10</sup>, MD, Cesare Porta<sup>63</sup>, MD, Luana Gentile<sup>18</sup>, MD, Ashraf Eskandari<sup>6</sup>, MD, Gian Marco De Marchis<sup>3</sup>, MD, MSc

- <sup>1</sup>Stroke Unit and Division of Cardiovascular Medicine, University of Perugia, Italy
- <sup>2</sup>Second Department of Neurology, “Attikon” University Hospital, National & Kapodistrian University of Athens, School of Medicine, Athens, Greece
- <sup>3</sup>Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Switzerland
- <sup>4</sup>Department of Neurology, Inselspital University Hospital and University of Bern, Switzerland
- <sup>5</sup>Department of Neurology, Helsinki University Hospital and Neurosciences University of Helsinki, Finland
- <sup>6</sup>Stroke Center, Neurology Service, Department of Clinical Neuroscience, Lausanne University Hospital and University of Lausanne, Switzerland
- <sup>7</sup>NeuroVascular Center and Stroke Unit Antwerp, Department of Neurology, Antwerp University Hospital, Antwerp, Belgium
- <sup>8</sup>Translational Neurosciences, Faculty of Medicine and Health Sciences, University of Antwerp, Belgium
- <sup>9</sup>Groeninge Hospital, Kortrijk, Belgium
- <sup>10</sup>Stroke Unit, DAI di Neuroscienze, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
- <sup>11</sup>Neurology Unit, AUSL - IRCCS of Reggio Emilia, Italy
- <sup>12</sup>School of Cardiovascular and Metabolic Health, University of Glasgow, United Kingdom
- <sup>13</sup>Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK
- <sup>14</sup>Struttura Complessa di Neurologia, Ente Ospedaliero Ospedali Galliera, Genoa, Italy
- <sup>15</sup>Department of Neurology, The Warren Alpert Medical School of Brown University, Providence, RI, USA
- <sup>16</sup>Department of Neurology, Duke University School of Medicine, Durham, North Carolina, USA
- <sup>17</sup>Internal Medicine, San Giuseppe Hospital, Empoli, Italy
- <sup>18</sup>Department of Human Neurosciences, Sapienza University of Rome, Italy
- <sup>19</sup>Stroke Unit – Emergency Department, Policlinico Umberto I, Rome, Italy
- <sup>20</sup>U.O. Neurologia Presidio Ospedaliero di Ravenna Azienda USL della Romagna, Italy
- <sup>21</sup>Neurology Unit, Azienda Ospedaliero-Universitaria Sant’Anna, Ferrara, Italy
- <sup>22</sup>Department of Neurology, Saarland University, Medical Center, Homburg, Germany
- <sup>23</sup>S.C. di Neurologia e S.S. di Stroke Unit, ASST di Mantova, Italy
- <sup>24</sup>Stroke Unit, Metropolitan Hospital, Piraeus, Greece
- <sup>25</sup>Stroke Unit, Department of Systems Medicine, University of Tor Vergata, Rome, Italy
- <sup>26</sup>Humanitas Clinical and Research Center - IRCCS, Rozzano, Milano, Italy
- <sup>27</sup>Neurology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
- <sup>28</sup>Department of Geriatrics, Neurosciences and Orthopedics, Università Cattolica del Sacro Cuore, Rome, Italy
- <sup>29</sup>Department of Neurology, Bogomolets National Medical University, Kyiv, Ukraine
- <sup>30</sup>S.C. Neurologia – Stroke Unit, Novi Ligure/Tortona, ASL Alessandria, Italy
- <sup>31</sup>Department of Neurology and Stroke Unit, Santa Corona Hospital, Pietra Ligure (Savona), Italy
- <sup>32</sup>Istituto Ospedaliero Fondazione Poliambulanza, Brescia, Italy
- <sup>33</sup>Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, Italy
- <sup>34</sup>Neurologia – Stroke Unit ARNAS Civico, Palermo, Italy
- <sup>35</sup>Stroke Unit, Ospedale di Portogruaro (Venice), Italy
- <sup>36</sup>Department of Medicine, University of Insubria, Ospedale di Circolo, Varese, Italy
- <sup>37</sup>Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece
- <sup>38</sup>Department of Neurology, University of Ioannina School of Medicine, Ioannina, Greece
- <sup>39</sup>Neurology and Stroke Unit, Department of Neuroscience, Bufalini Hospital, Cesena, Italy
- <sup>40</sup>L. Sacco' Department of Biomedical and Clinical Sciences, University of Milan, Italy
- <sup>41</sup>Neurology Unit, ASST Fatebenefratelli – Sacco, Milan, Italy
- <sup>42</sup>Neurologia, Ospedale Apuano, Massa Carrara, Italy
- <sup>43</sup>Emergency Neurology, IRCCS Casimiro Mondino Foundation, Pavia, Italy
- <sup>44</sup>Cerebrovascular Unit, Fondazione IRCCS Istituto Neurologico “Carlo Besta”, Milano, Italy
- <sup>45</sup>Unità di Terapia Neurovascolare. Ospedale "Fabrizio Spaziani", Frosinone, Italy
- <sup>46</sup>Stroke Unit, Department of Neurology, Sant'Andrea Hospital, La Spezia, Italy
- <sup>47</sup>Department of Neurology, Ospedale San Paolo, Savona, Italy
- <sup>48</sup>Neurologia, Ospedali Riuniti, Palermo, Italy
- <sup>49</sup>Department of Clinical and Experimental Sciences, Neurology Unit, University of Brescia, Italy
- <sup>50</sup>Neuroscience Section, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy.
- <sup>51</sup>Clinic of Neurology, University Clinical Center of Vòsvodina, University of Novi Sad, Serbia
- <sup>52</sup>Stroke Unit, Emergency Department, University of Parma, Italy
- <sup>53</sup>Stroke Unit - Dipartimento Geriatrico Riabilitativo – University of Parma, Italy
- <sup>54</sup>Stroke and Neurorehabilitation Unit MC ‘Universal Clinic ‘Oberig’ Kyiv, Ukraine
- <sup>55</sup>Department of Clinical and Experimental Medicine, Neurological Institute, University of Pisa, Italy
- <sup>56</sup>Department of Neurology, Democritus University of Thrace, University Hospital of Alexandroupolis, Greece
- <sup>57</sup>Neurology & Stroke Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
- <sup>58</sup>Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg and Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden
- <sup>59</sup>UO Gravi Cerebrolesioni, San Giovanni Battista Hospital, Foligno, Italy
- <sup>60</sup>SC Medicina e Chirurgia d’Accettazione e d’Urgenza, Ospedale Lotti Pontedera, Azienda USL Toscana Nordovest
- <sup>61</sup>Stroke Unit, AOU Senese, Siena, Italy
- <sup>62</sup>Department of Neurology, Keimyung University School of Medicine, Daegu, South Korea
- <sup>63</sup>Internal Medicine Unit, Magenta Hospital, ASST Ovest Milanese, Magenta (MI), Italy
- <sup>64</sup>Program Director for Vascular Neurology (Stroke) Fellowship Program, Stroke/Vascular Neurologist Clinical, Associate Professor of Neurology, ABPN Diplomate, Board Certified in Neurology and Vascular Neurology, Geisinger Health System, USA

<sup>65</sup>Neurologia, Azienda Ospedaliera dell'Alto Adige, Italy

<sup>66</sup>Stroke Unit, Jazzolino Hospital, Vibo Valentia, Italy

<sup>67</sup>Department of Neurology, Evangelismos Hospital, Athens

<sup>68</sup>2<sup>nd</sup> Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Greece

<sup>69</sup>Neurologia, Ospedale Apuano, Massa Carrara, Italy

<sup>70</sup>2<sup>nd</sup> Department of Neurology, AHEPA University Hospital, Thessaloniki, Greece

<sup>71</sup>Abteilung für Neurologie, Oberschwabenklinik gGmbH, Ravensburg, Germany

<sup>72</sup>Stroke Unit, University of Debrecen, Hungary

<sup>73</sup>Department of Internal Medicine, Ospedale Civile di Piacenza, Italy

<sup>74</sup>Stroke Unit, Azienda Ospedaliera Università di Padova, Padova, Italy

<sup>75</sup>Department of Neurology, Dresden University Stroke Center, Dresden, Germany

<sup>76</sup>Municipal Budgetary Healthcare Institution of Novosibirsk. City Clinical Hospital # 1. Novosibirsk (Russia) at the Novosibirsk State Medical University (Russia)

<sup>77</sup>Neurology, Hamad Medical Corporation, Doha, Qatar

**Disclosures of RAF and RENO-Extend Investigators:** M. Paciaroni received honoraria as a member of the speaker bureau of Sanofi-Aventis, Bayer, Bristol Meyer Squibb, Daiichi Sankyo and Pfizer. G. Agnelli received honoraria as a member of the speaker bureau of Boehringer Ingelheim and Bayer. C. Becattini received honoraria as a member of the speaker bureau of Bristol Meyer Squibb and Bayer. P. Michel received Research Grant by Swiss National Science Foundation and Swiss Heart Foundation; he received speaker fees by Bayer, Boehringer Ingelheim, Covidien, St. Jude Medical; he received honoraria as advisory relationship by Pierre-Fabre, Bayer, Bristol Meyer Squibb, Amgen, and Boehringer Ingelheim. J. Putaala has received personal fees from Boehringer Ingelheim, Bayer, and Portola. He has also received grants and personal fees from BMS-Pfizer and Abbott/St Jude Medical. T. Tatlisumak received honoraria as consultant or advisory relationship from Bayer, Boehringer Ingelheim, Bristol Meyer Squibb, Lumosa Pharm and Portola Pharma. G. Tsivgoulis has received funding for travel or speaker's honoraria from Bayer, Pfizer, and Boehringer Ingelheim. He has served on scientific advisory boards for Bayer, Boehringer Ingelheim, and Daiichi Sankyo. D. Toni has received personal fees from Abbott, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Medtronic, and Pfizer. V. Caso received honoraria as a member of the speaker bureau of Boehringer Ingelheim, Bayer, and Daiichi Sankyo (all fees were paid to Associazione Ricerca Stroke, Umbria). She received honoraria as consultant or advisory board member of Boehringer Ingelheim, Bayer, Daiichi Sankyo, and Pfizer. W. Ageno has received speaker's honoraria from, and participated in scientific advisory boards for Boehringer Ingelheim, Bayer, Bristol-Myers Squibb/Pfizer, and Daiichi Sankyo and has received research support from

Bayer and Boehringer Ingelheim. J. Dawson reports honoraria as a member of the speaker bureau of Boehringer Ingelheim, Bayer, BMS, Daiichi Sankyo, Medtronic and Pfizer. He has also received research funding from Pfizer. G. Ntaios reports speaker fees/advisory board/ research support from Bayer, Pfizer, Boehringer Ingelheim and Elpen. All fees are paid to his institution. S. Sacco has received personal fees as speaker or advisor from Abbott, Allergan, Astra Zeneca, Eli Lilly, Lundbeck, Novartis, NovoNordisk, Teva and research grants from Allergan, Novartis, and Uriach. P. Vanacker received honoraria as a member of the speaker bureau and as advisory board of Boehringer Ingelheim, Bristol Meyer Squibb, Daiichi Sankyo, Medtronic, EG and Pfizer. M. Del Sette has received honoraria for speaking from Bayer and Boehringer Ingelheim. M. Zedde received speaking and consulting fees from Daiichi Sankyo, Amicus Therapeutics, Sanofi Genzyme, Abbott, and Takeda. M. Cappellari has received consulting fees from Boehringer Ingelheim, Pfizer – BMS, and Daiichi Sankyo. Y. Flomin has received personal fees from Boehringer Ingelheim, Bayer and Takeda, grants, personal fees and nonfinancial support from Pfizer, personal fees and nonfinancial support from Sanofi Genzyme. E. Rota has received speaker fees from Bayer and Novartis. C. Stretz has received departmental funding from Massachusetts General Hospital/Boston Scientific for his site's participation in the Neuro Afib study. R. Ornello has received nonfinancial support from Novartis, Allergan, and Teva. S. Giannopoulos has received funding for travel from Bayer and speaker's honoraria from Pfizer. D. Strbian received honoraria from Portola and BMS for participation in scientific advisory board and unrestricted educational grant from Boehringer Ingelheim.

The other authors report no conflicts.

**Table S1.** Characteristics of the patients with combined event (ischemic stroke, systemic embolism, symptomatic intracranial hemorrhage, severe extracranial bleeding): 382 events were recorded in 375 patients.

	<b>With combined outcome (N=375)</b>	<b>Without combined outcome (N=3071)</b>	<b>p</b>
Age, years - mean (median)	78.0±9.1 (79)	76.2±9.8 (77)	0.01
Male sex	190 (50.7%)	1460 (47.5%)	0.2
Diabetes mellitus	120 (32.0%)	719 (23.4%)	<0.0001
Hypertension	332 (88.5%)	2445 (79.6%)	<0.0001
Hyperlipidemia	174 (46.4%)	1227 (39.9%)	0.02
Paroxysmal AF	160 (42.7%)	1375 (44.8%)	0.4
History of stroke/TIA	127 (33.9%)	912 (29.7%)	0.1
Current smoker	93 (24.8%)	587 (19.1%)	0.01
Alcoholism	29 (7.7%)	227 (7.4%)	0.7
History of myocardial infarction	82 (21.9%)	533 (17.4%)	0.04
Leukoaraiosis	230 (61.3%)	1653 (53.8%)	0.007
Oral anticoagulant therapy	295 (78.7%)	2568 (86.5%)	<0.0001
Statin therapy	150 (40.0%)	1008 (32.8%)	0.008
Antiplatelet associated with oral anticoagulant	81 (21.6%)	326 (10.6%)	<0.0001
CHA <sub>2</sub> DS <sub>2</sub> VASc > 3	328 (87.5%)	2602 (84.7%)	0.1
EF ≤ 40%	86 (22.9%)	552 (18.0%)	0.02

**Table S2.** Characteristics of the patients with ischemic event (ischemic stroke and systemic embolism).

	<b>With ischemic event (N=230)</b>	<b>Without ischemic event (N=3247)</b>	<b>p</b>
Age, years - mean (median)	78.2±9.3 (80)	76.2±9.8 (77)	0.03
Male sex	113 (49.1%)	1537 (47.3%)	0.7
Diabetes mellitus	75 (32.6%)	764 (23.5%)	0.004
Hypertension	204 (88.7%)	2573 (79.2%)	0.001
Hyperlipidemia	108 (46.9%)	1293 (39.8%)	0.05
Paroxysmal AF	95 (41.3%)	1440 (44.3%)	0.3
History of stroke/TIA	87 (37.8%)	952 (29.3%)	0.01
Current smoker	60 (26.1%)	620 (19.1%)	0.01
Alcoholism	17 (7.4%)	239 (7.4%)	1.0
History of myocardial infarction	53 (23.0%)	562 (17.3%)	0.04
Leukoaraiosis	141 (61.3%)	1742 (53.6%)	0.03
Oral anticoagulant therapy	185 (80.4%)	2768 (85.2%)	0.03
Statin therapy	95 (41.3%)	1063 (32.7%)	0.01
Antiplatelet associated with oral anticoagulant	50 (21.7%)	357 (11.0%)	<0.0001
CHA <sub>2</sub> DS <sub>2</sub> VASc > 3	203 (88.3%)	2727 (84.0%)	0.1
EF ≤ 40%	58 (25.2%)	580 (17.9%)	0.01



**Table S3.** Characteristics of the patients with hemorrhagic event (symptomatic intracranial hemorrhage and severe extracranial bleeding).

	<b>With hemorrhagic event (N=152)</b>	<b>Without hemorrhagic outcome (N=3325)</b>	<b>p</b>
Age, years - mean (median)	78.0±8.6 (79)	76.2±9.8 (77)	0.1
Male sex	82 (53.9%)	1568 (47.2%)	0.1
Diabetes mellitus	46 (30.3%)	793 (23.8%)	0.1
Hypertension	133 (87.5%)	2644 (79.5%)	0.03
Hyperlipidemia	68 (44.7%)	1333 (40.1%)	0.3
Paroxysmal AF	65 (42.8%)	1470 (44.2%)	0.6
History of stroke/TIA	39 (25.7%)	1000 (30.1%)	0.2
Current smoker	32 (21.0%)	648 (19.5%)	0.6
Alcoholism	14 (9.2%)	242 (7.3%)	0.2
History of myocardial infarction	31 (20.4%)	584 (17.6%)	0.3
Leukoaraiosis	95 (62.5%)	1788 (53.8%)	0.05
Oral anticoagulant therapy	113 (74.3%)	2840 (85.4%)	<0.0001
Statin therapy	56 (36.8%)	1102 (33.1%)	0.4
Antiplatelet associated with oral anticoagulant	32 (21.1%)	375 (11.3%)	0.001
CHA <sub>2</sub> DS <sub>2</sub> VASc > 3	132 (86.8%)	2798 (84.2%)	0.6
EF ≤ 40%	29 (19.1%)	609 (18.3%)	0.8

**Table S4.** Characteristics of the patients with EF  $\leq$  40% treated with NOACs or with vitamin K antagonists.

	<b>NOAC (N=421)</b>	<b>Vitamin K antagonist (N=129)</b>	<b>p</b>
Age, years - mean (median)	77.4 $\pm$ 10.5 (80)	74.6 $\pm$ 10.1 (77)	0.02
NIHSS, mean (median)	7.7 $\pm$ 5.6 (6)	8.1 $\pm$ 6.7 (6)	0.04
Male sex	224 (53.2%)	70 (54.3%)	0.8
Diabetes mellitus	127 (30.2%)	40 (31.0%)	0.9
Hypertension	350 (83.1%)	109 (84.4%)	0.8
Hyperlipidemia	196 (46.5%)	55 (42.6%)	0.4
Paroxysmal AF	141 (33.5%)	33 (25.6%)	0.08
History of stroke/TIA	141 (33.5%)	39 (30.2%)	0.6
Current smoker	93 (22.1%)	10 (7.8%)	<0.0001
Alcoholism	45 (10.7%)	16 (12.4%)	0.6
History of myocardial infarction	148 (35.2%)	41 (31.8%)	0.4
Leukoaraiosis	278 (66.0%)	56 (43.4%)	<0.0001
Antiplatelet associated with oral anticoagulant	27 (6.4%)	36 (27.9%)	<0.0001
CHA <sub>2</sub> DS <sub>2</sub> VASc > 3	386 (91.7%)	122 (94.6%)	0.3
Combined endpoint	47 (11.2%)	26 (20.2%)	0.02
Ischemic endpoint	32 (7.6%)	17 (13.2%)	0.07
Hemorrhagic endpoint	14 (3.3%)	9 (7.0%)	0.08